| John Clifton Gorsline, MD | |
|
516 W Margaret, Suite 9, Pasco, WA 99301 | |
| (509) 542-8232 | |
| (509) 547-6747 |
| Full Name | John Clifton Gorsline |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 516 W Margaret, Pasco, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043282577 | NPI | - | NPPES |
| 8247827 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD00030350 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| John Clifton Gorsline, MD 516 W Margaret, Suite 9, Pasco, WA 99301 Ph: (509) 542-8232 | John Clifton Gorsline, MD 516 W Margaret, Suite 9, Pasco, WA 99301 Ph: (509) 542-8232 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.
As the coronavirus disease 19 (COVID-19) pandemic appears here to stay, a new study published on the preprint server bioRxiv* in November 2020 reports an effective and rapid inactivation tactic for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); namely, through the use of ozone water.
Patients with Type 1 Diabetes have a brain connectivity network different from the healthy people, according to a new study led by researchers of the Institute of Neurosciences and the Institute of Complex Systems of the University of Barcelona.
Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that combination treatment with milatuzumab, the first humanized anti-CD74 antibody in clinical testing, and veltuzumab, a second-generation humanized anti-CD20 antibody, resulted in therapeutic responses in heavily pretreated and rituximab-refractory non-Hodgkin's lymphoma patients.
An inexpensive type 2 diabetes drug that has been around for more than 15 years works just as well and has fewer side effects than a half-dozen other, mostly newer and more expensive classes of medication used to control the chronic disease, new Johns Hopkins research suggests.
› Verified 4 days ago
Dr. Bradley J. Logston, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 9613 Sandifur Pkwy Ste A, Pasco, WA 99301 Phone: 509-943-8839 Fax: 509-943-8851 | |
Dr. Graham Francis Loynd, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 6107 Cowlitz Ln, Pasco, WA 99301 Phone: 509-542-9375 | |
Dr. Edward H Temple, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5908 Bedford St, Suite C, Pasco, WA 99301 Phone: 509-547-4724 Fax: 509-547-2056 | |
Dr. Tomas A Hernandez-mejia, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 5908 Bedford St, Pasco, WA 99301 Phone: 509-547-4724 Fax: 509-547-4881 | |
Valiant W S Chou, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1200 N 14th Ave, #255, Pasco, WA 99301 Phone: 509-547-7536 Fax: 509-544-6648 | |
Enriqueta Mayuga, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 531 W Park St, Suite 1, Pasco, WA 99301 Phone: 509-547-5261 |